Zevra Therapeutics (ZVRA) Stock: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$12.01
-0.05 (-0.41%)
▼
5d:
-4.23%
30d:
+4.98%
90d:
-7.4%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZVRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZVRA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.85
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$6.12
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $12.01, which is considered extended relative to its 30-day fair value range of $10.86 to $12.28. The stock's valuation (Forward PE: 11.4) is in line with its historical norms (10.4). At these levels, the market is pricing in 3.3% annual earnings growth.
Technical Outlook: Technically, ZVRA is in a uptrend. Immediate support is located at $11.39, while resistance sits at $12.90.
Market Sentiment: ZVRA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZVRA is in a uptrend. Immediate support is located at $11.39, while resistance sits at $12.90.
Market Sentiment: ZVRA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.86 -
$12.28
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.9%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 108.2% below Wall St target ($25.00)
- BULLISH: Expecting earnings turnaround to 3.3% growth with 53.3% revenue growth
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.86 -
$12.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.39
Resistance Level
$12.90
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.44
Wall Street Target
$25.00
(+108.2%)
Revenue Growth (YoY)
53.3%
Earnings Growth (YoY)
-88.4%
Profit Margin
42.8%
Valuation Premium vs History
+3.3% premium
PE vs Historical
11.4 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.3%
(market-implied from PE analysis)
1-Year Target
$12.41
(+3%)
2-Year Target
$12.82
(+7%)
3-Year Target
$13.24
(+10%)
3-Yr Target (if PE normalizes)
(PE: 11→10)
PE COMPRESSION
$12.04
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -7.9%)
$16.55
(+38%)
Base:
(SPY PE: 11.4, Growth: -7.9%)
$9.38
(-22%)
Bear:
(PE: 9.7, Growth: -7.9%)
$7.98
(-34%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 12.97 | Current EPS (TTM): $0.93
Bull Case
$14.98
(+25%)
Analyst growth 12.9%, PE expands to 14.3
Base Case
$13.62
(+13%)
Market implied 12.9%, PE stable at 13.0
Bear Case
$8.20
(-32%)
Severe decline -20.0%, PE contracts to 11.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 2:39 AM ET
Data refreshes hourly during market hours. Next update: 3:39 AM
Data refreshes hourly during market hours. Next update: 3:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
